Scherak O, Weissel M, Fritzsche H, Kolarz G
Int J Clin Pharmacol Biopharm. 1976 Sep;14(2):86-92.
In 16 healthy volunteers tolbutamide tests or i.v. glucose tolerance tests were performed with and without previous oral administration of 1000 mg diftalone. Blood sugar and serum insulin were assayed in regular intervals. Both with and without previous administration of diftalone blood glucose after tolbutamide did not show any difference. IRI response to tolbutamide, measured by planimetrical integration showed a statistically significant augmentation (0.05 greater than p greater than 0.01) after diftalone. Glucose assimilation (K-value) after diftalone was decreased (0.05 greater than p greater than 0.01) yet within normal range. For the accompanying insulin levels however no statistically significant difference was observed. In addition a normalisation of pathological tolbutamide test after diftalone could be noted in five patients with subclinical diabetes. Our results indicate that diftalone seems to have the following three actions: 1. Enhancement of the tolbutamide action. 2. direct augmentation of IRI secretion, 3. a peripheral action on glucose metabolism.
对16名健康志愿者进行了甲苯磺丁脲试验或静脉葡萄糖耐量试验,试验分在口服1000毫克双苯磺丁脲前后进行。定期测定血糖和血清胰岛素。无论之前是否服用双苯磺丁脲,甲苯磺丁脲后的血糖均无差异。通过平面测量积分法测定,双苯磺丁脲后IRI对甲苯磺丁脲的反应有统计学显著增强(0.05>p>0.01)。双苯磺丁脲后的葡萄糖同化(K值)降低(0.05>p>0.01),但仍在正常范围内。然而,伴随的胰岛素水平未观察到统计学显著差异。此外,在5例亚临床糖尿病患者中,双苯磺丁脲后病理性甲苯磺丁脲试验可恢复正常。我们的结果表明双苯磺丁脲似乎有以下三种作用:1.增强甲苯磺丁脲作用。2.直接增强IRI分泌。3.对葡萄糖代谢的外周作用。